News
LFCR
6.69
+5.94%
0.38
Lifecore Biomedical Faces Nasdaq Delisting Challenges
TipRanks · 11h ago
Lifecore Biomedical gets Nasdaq notice regarding delayed quarterly report
Seeking Alpha · 11h ago
Lifecore Biomedical, Inc. Receives Notice From Nasdaq Regarding Delayed Quarterly Report For The Fiscal Quarter Ended February 25, 2024 And Its Continued Delay In Filing Its Quarterly Report On Form 10-Q For The Quarterly Periods Ended August 27, 2023 And November 29, 2023
Lifecore Biomedical, Inc. Received a notification letter from Nasdaq on April 15, 2024. The Company continues not to be in compliance with the requirements for continued listing on the Nasdaq Global Select Market. The Notice has no immediate effect on the listing or trading of the Company's common stock.
Benzinga · 11h ago
LIFECORE BIOMEDICAL, INC. RECEIVES NOTICE FROM NASDAQ REGARDING DELAYED QUARTERLY REPORT
Reuters · 11h ago
Laughing Water Capital Q1 2024 Letter
Seeking Alpha · 1d ago
White Falcon Capital Q1 2024 Partner's Letter
White Falcon Capital delivered a satisfactory result on an absolute basis in the first quarter of 2024. The big detractors were Endava and Lifecore Biomedical. White Falcon Capital's investment in Converge Technology Solution was not an easy to hold investment. The company's goal is to protect and compound capital over the long term.
Seeking Alpha · 3d ago
Weekly Report: what happened at LFCR last week (0408-0412)?
Weekly Report · 4d ago
ROSEN, A TOP RANKED LAW FIRM, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to Inquire About Securities Class Action Investigation – LFCR, LNDC
Rosen Law Firm is preparing a class action on behalf of shareholders of Lifecore Biomedical Inc. F/k/a Landec Corporation (NASDAQ: LFCR, LNDC) The Rosen Law Firm says the company may have issued materially misleading business information to the investing public.
Barchart · 04/11 09:36
Weekly Report: what happened at LFCR last week (0401-0405)?
Weekly Report · 04/08 09:18
LIFECORE BIOMEDICAL INC <LFCR.O>: STEPHENS CUTS TARGET PRICE TO $6 FROM $8
Reuters · 04/03 04:37
*Lifecore Biomedical Sees FY24 Rev $125M-$130M >LFCR
Dow Jones · 04/01 12:03
LIFECORE BIOMEDICAL PROVIDES BUSINESS UPDATE OUTLINING FISCAL 2024 OUTLOOK AND YEAR-TO-DATE PROGRESS
Reuters · 04/01 12:00
LIFECORE BIOMEDICAL INC: BELIEVES IT HAS SUFFICIENT LIQUIDITY TO ACHIEVE ITS STRATEGIC PLAN OVER NEXT 12 MONTHS AS OF DATE HEREOF
Reuters · 04/01 12:00
LIFECORE BIOMEDICAL INC: SEES 2024 REVENUE TO BE IN RANGE OF $125 MLN TO $130 MLN
Reuters · 04/01 12:00
Press Release: Lifecore Biomedical Provides Business Update Outlining Fiscal 2024 Outlook and Year-to-date Progress
Lifecore Biomedical Provides Business Update Outlining Fiscal 2024 Outlook and Year-to-date Progress. The Company continues to see growth in its pipeline opportunities for development and late-stage programs. Lifecore expects to triple its current manufacturing capacity in fiscal year 2024. The company has 33 projects in development and is working to expand capacity.
Dow Jones · 04/01 12:00
Press Release: Lifecore Biomedical Provides -2-
Lifecore believes its capital structure remains in a stable condition following its comprehensive refinancing in May 2023. The Company believes it has sufficient liquidity to achieve its strategic plan over the next 12 months. Fiscal 2024 revenue is expected to be in the range of $125 million to $130 million.
Dow Jones · 04/01 12:00
Weekly Report: what happened at LFCR last week (0325-0329)?
Weekly Report · 04/01 09:18
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Lifecore Biomedical, Inc. (LFCR) on Behalf of Investors
Glancy Prongay & Murray LLP has commenced an investigation on behalf of Lifecore Biomedical, Inc. Investors concerning the Company’s possible violations of the federal securities laws. The company filed restated financial statements for fiscal year 2024 to correct errors. On March 20, 2024, the stock price fell 30.3% to $5.01 per share.
Barchart · 03/28 14:00
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Lifecore Biomedical, Inc. (LFCR) on Behalf of Investors
Lifecore Biomedical, Inc. Filed restated financial statements for fiscal year 2021 and 2022 on March 20, 2024. On this news, Lifecore’s stock price fell $2.18, or 30.3%, to close at $5.01 per share. Law Offices of Howard G. Smith is investigating possible violations of federal securities laws.
Barchart · 03/28 11:47
The Law Offices of Frank R. Cruz Announces Investigation of Lifecore Biomedical, Inc. (LFCR) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of Lifecore Biomedical, Inc. On behalf of investors. The Company filed restated financial statements for fiscal year 2021 and 2022 on March 20, 2024. On this news, the stock price fell $2.18, or 30.3%, to close at $5.01.
Barchart · 03/26 19:31
More
Webull provides a variety of real-time LFCR stock news. You can receive the latest news about Lifecore Biomedical Inc through multiple platforms. This information may help you make smarter investment decisions.
About LFCR
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.